BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $262,046 | +0.9% | 37,012 | +0.4% | 0.00% | 0.0% |
| Q2 2023 | $259,621 | -10.8% | 36,878 | +5.7% | 0.00% | 0.0% |
| Q1 2023 | $291,041 | -35.5% | 34,897 | -11.2% | 0.00% | -50.0% |
| Q4 2022 | $450,992 | -0.9% | 39,285 | +8.9% | 0.00% | 0.0% |
| Q3 2022 | $455,000 | +21.7% | 36,083 | +2.2% | 0.00% | +100.0% |
| Q2 2022 | $374,000 | -56.5% | 35,293 | -33.2% | 0.00% | -50.0% |
| Q1 2022 | $860,000 | -3.8% | 52,869 | -18.1% | 0.00% | 0.0% |
| Q4 2021 | $894,000 | +1.9% | 64,573 | +5.9% | 0.00% | 0.0% |
| Q3 2021 | $877,000 | -28.9% | 60,998 | -21.9% | 0.00% | -50.0% |
| Q2 2021 | $1,234,000 | +69.3% | 78,054 | +8.9% | 0.00% | +100.0% |
| Q1 2021 | $729,000 | +47.3% | 71,674 | +8.0% | 0.00% | 0.0% |
| Q4 2020 | $495,000 | +187.8% | 66,380 | +32.5% | 0.00% | +100.0% |
| Q3 2020 | $172,000 | -25.9% | 50,107 | +3.1% | 0.00% | 0.0% |
| Q2 2020 | $232,000 | +286.7% | 48,619 | +61.0% | 0.00% | – |
| Q1 2020 | $60,000 | -67.4% | 30,205 | -43.4% | 0.00% | -100.0% |
| Q4 2019 | $184,000 | +50.8% | 53,393 | +25.8% | 0.00% | 0.0% |
| Q3 2019 | $122,000 | -26.5% | 42,441 | -3.0% | 0.00% | 0.0% |
| Q2 2019 | $166,000 | -58.5% | 43,755 | -10.9% | 0.00% | -50.0% |
| Q1 2019 | $400,000 | +1.8% | 49,111 | +0.9% | 0.00% | -33.3% |
| Q4 2018 | $393,000 | -11.1% | 48,660 | -16.0% | 0.00% | 0.0% |
| Q3 2018 | $442,000 | +41.7% | 57,953 | +6.3% | 0.00% | +50.0% |
| Q2 2018 | $312,000 | +12.6% | 54,502 | -6.1% | 0.00% | 0.0% |
| Q1 2018 | $277,000 | -16.6% | 58,035 | -14.1% | 0.00% | 0.0% |
| Q4 2017 | $332,000 | +24.8% | 67,561 | +33.0% | 0.00% | 0.0% |
| Q3 2017 | $266,000 | -1.1% | 50,807 | +5.1% | 0.00% | -33.3% |
| Q2 2017 | $269,000 | -33.3% | 48,354 | +0.9% | 0.00% | -25.0% |
| Q1 2017 | $403,000 | +5.2% | 47,927 | -20.8% | 0.00% | 0.0% |
| Q4 2016 | $383,000 | +61.6% | 60,527 | +12.6% | 0.00% | +33.3% |
| Q3 2016 | $237,000 | +30.9% | 53,737 | -15.8% | 0.00% | +50.0% |
| Q2 2016 | $181,000 | +1.7% | 63,843 | +1.4% | 0.00% | 0.0% |
| Q1 2016 | $178,000 | -75.2% | 62,967 | -9.4% | 0.00% | -77.8% |
| Q4 2015 | $718,000 | +0.3% | 69,532 | +10.8% | 0.01% | -10.0% |
| Q3 2015 | $716,000 | -28.5% | 62,777 | -6.4% | 0.01% | -28.6% |
| Q2 2015 | $1,002,000 | +55.3% | 67,096 | -6.1% | 0.01% | +75.0% |
| Q1 2015 | $645,000 | -15.2% | 71,441 | +14.2% | 0.01% | -11.1% |
| Q4 2014 | $761,000 | +20.2% | 62,577 | -3.3% | 0.01% | +12.5% |
| Q3 2014 | $633,000 | -35.2% | 64,742 | -15.5% | 0.01% | -38.5% |
| Q2 2014 | $977,000 | +104.0% | 76,608 | +69.4% | 0.01% | +116.7% |
| Q1 2014 | $479,000 | +143.1% | 45,235 | +74.7% | 0.01% | +100.0% |
| Q4 2013 | $197,000 | +264.8% | 25,886 | -25.2% | 0.00% | +200.0% |
| Q2 2013 | $54,000 | – | 34,599 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 7,637,700 | $77,675,000 | 7.44% |
| Burrage Capital Management LLC | 864,916 | $8,796,000 | 7.13% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,367,670 | $24,079,000 | 3.61% |
| HealthCor Management, L.P. | 4,886,440 | $49,695,000 | 1.76% |
| Ghost Tree Capital, LLC | 500,000 | $5,085,000 | 1.20% |
| Integral Health Asset Management, LLC | 400,000 | $4,068,000 | 1.16% |
| Lisanti Capital Growth, LLC | 472,520 | $4,806,000 | 0.62% |
| Parkman Healthcare Partners LLC | 244,680 | $2,488,000 | 0.58% |
| Baker Brothers Advisors | 12,710,818 | $129,269,000 | 0.56% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,605,380 | $26,497,000 | 0.56% |